Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
Metreleptin's approval for generalized lipodystrophy is the first step in defining and expanding its role to other metabolic diseases. Clinical trials are underway to delineate its efficacy in FPLD, human immunodeficiency virus/highly active anti-retroviral therapy-associated acquired lipodystrophy (HAL), and NAFLD. Additionally, there is growing data that support a therapeutic role in obesity. One of the barriers to development, however, is metreleptin's safety and immunogenicity. Further advances in biologic compatibility are required before metreleptin can be approved for additional indications.
|
Authors | Beverly G Tchang, Alpana P Shukla, Louis J Aronne |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 15
Issue 7
Pg. 1061-75
(Jul 2015)
ISSN: 1744-7682 [Electronic] England |
PMID | 26063386
(Publication Type: Journal Article, Review)
|
Chemical References |
- Leptin
- recombinant methionyl human leptin
- metreleptin
|
Topics |
- Autoimmunity
- Clinical Trials as Topic
- Half-Life
- Humans
- Leptin
(analogs & derivatives, chemistry, metabolism, pharmacokinetics, therapeutic use)
- Lipodystrophy
(classification, drug therapy, etiology)
- Lipodystrophy, Congenital Generalized
(classification, drug therapy, etiology)
- Obesity
(drug therapy)
- Signal Transduction
|